According to recommendations from KDIGO 2021 (Kidney Disease: ImprovingGlobal Outcomes)10, in patients with nephrotic syndrome and stable GFR, the serum dosage ofanti-PLA2R antibody by ELISA and indirect immunofluorescence assay may besufficient. Here, PLA2R1 is linked to kidney disorder.